Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $6.5052W HIGH $33.50
Volume
1.10 M
Value Traded
14.04 M
Short % Float
24.37%
+7.1%Week
-10.92%1 Month
+10.37%3 Month
+24.61%6 Month
-96.75%5 Year
-98.29%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.18 B
EPS (TTM)
-21.45
P/E Ratio
-
Ent. Value
711.20 M
Total Shares
59.16 M
Float Shares
32.43 M
Insiders
45.18%
Institutions
62.60%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
VOR Catalyst Timeline
Dated clinical, regulatory and corporate events for Vor Biopharma Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vor Biopharma Inc.
315Total events
8Upcoming
62Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Oral PresentationTelitaciceptApprovedPresentation
Telitacicept 48-week post hoc analysis presented at 2026 AANEM Annual Meeting MGFA Scientific Session
generalized myasthenia gravissource ↗
▲Additional DataTelitaciceptApprovedClinical Data
Post hoc 48-week analysis: 42% achieved MSE, 86.7% of MSE events sustained, >94% achieved ≥5-point MG-ADL improvement
generalized myasthenia gravissource ↗
▲Enrollment CompleteTelitaciceptApprovedTrial
Vor Bio completes enrollment in global Phase 3 UPSTREAM MG trial of telitacicept in gMG
generalized myasthenia gravissource ↗
●Enrollment UpdateTelitaciceptApprovedTrial
Enrollment ongoing for Phase 3 UPSTREAM SjD trial
primary Sjögren’s diseasesource ↗
▲NMPA NDA ApprovalTelitaciceptApprovedEx-US Regulatory
NMPA conditional approval for IgA nephropathy
IgA nephropathysource ↗
▲Primary Endpoint MetTelitaciceptApprovedClinical Data
Phase 3 TELIGAN met primary endpoint
IgA nephropathysource ↗
▲PublicationTelitaciceptApprovedPresentation
TELIGAN results published in New England Journal of Medicine
IgA nephropathysource ↗
▲Full ResultsTelitaciceptApprovedClinical Data
Interim analysis of TELIGAN published in NEJM
IgA nephropathysource ↗
▲Primary Endpoint MetTelitaciceptApprovedClinical Data
Primary endpoint met: statistically significant reduction in proteinuria at week 39
IgA nephropathysource ↗
◆Enrollment UpdateTelitaciceptApprovedTrial
Enrollment ongoing for Phase 3 UPSTREAM SjD trial of telitacicept in SjD
primary Sjögren's diseasesource ↗
▲First Patient DosedTelitaciceptApprovedTrial
First patient dosed in global Phase 3 trial UPSTREAM SjD for telitacicept in primary Sjögren's disease
primary Sjögren's diseasesource ↗
●Enrollment UpdateTelitaciceptApprovedTrial
Enrollment ongoing globally in Phase 3 trial UPSTREAM MG for telitacicept in gMG
generalized myasthenia gravissource ↗
▼Equity OfferingCorporate
$75 million private placement with TCGX to advance telitacicept clinical development
▲Trial InitiationTelitaciceptApprovedTrial
Initiated global Phase 3 trial UPSTREAM SjD for telitacicept in primary Sjögren's disease
primary Sjögren's diseasesource ↗
◆Oral PresentationPresentation
TD Cowen Virtual Immunology & Inflammation Summit Fireside Chat
▼Equity OfferingCorporate
Pricing of $100 million public offering of common stock at $10.00 per share
▲Primary Endpoint MetTelitaciceptApprovedClinical Data
Telitacicept achieved primary endpoint of reducing proteinuria in Stage A of Phase 3 study for IgAN
IgA nephropathysource ↗
●BLA SubmissionTelitaciceptApprovedRegulatory Filing
BLA submitted to NMPA CDE in China for IgAN
IgA nephropathysource ↗
◆Late-BreakerTelitaciceptApprovedPresentation
Late-breaking oral presentation of Phase 3 IgAN data at ASN Kidney Week 2025
IgA nephropathysource ↗
▼Equity OfferingCorporate
Underwritten public offering with expected gross proceeds of $115 million
◆Oral PresentationTelitaciceptApprovedPresentation
Oral presentation of 48-week Phase 3 data for telitacicept in gMG at AANEM
generalized myasthenia gravissource ↗
▲Full ResultsTelitaciceptApprovedClinical Data
48-week open-label extension data from Phase 3 China trial
generalized myasthenia gravissource ↗
▲Trial InitiationTelitaciceptApprovedTrial
Global Phase 3 trial now enrolling across 14 countries
generalized myasthenia gravissource ↗
◆Oral PresentationTelitaciceptApprovedPresentation
Webcast to present late-breaking 48-week Phase 3 data for telitacicept in primary Sjögren's disease
primary Sjögren's diseasesource ↗
▲Poster PresentationTelitaciceptApprovedPresentation
Late-breaking poster presentation at ACR Convergence 2025
Sjögren's diseasesource ↗
▲Full ResultsTelitaciceptApprovedClinical Data
48-week Phase 3 clinical trial data from China for telitacicept in primary Sjögren's disease
primary Sjögren's diseasesource ↗
●NDA SubmissionTelitaciceptApprovedRegulatory Filing
BLA submitted to NMPA CDE in China for IgAN
IgA nephropathysource ↗
▲Primary Endpoint MetTelitaciceptApprovedClinical Data
Phase 3 study of telitacicept in SLE met primary endpoint with 67.1% vs 32.7% SRI-4 response
systemic lupus erythematosussource ↗
▲PublicationTelitaciceptApprovedPresentation
Publication of Phase 3 SLE study results in The New England Journal of Medicine
systemic lupus erythematosussource ↗
▲Topline ReadoutTelitaciceptApprovedClinical Data
Positive top-line Phase 3 results in Sjögren's disease in China
Sjögren's diseasesource ↗
▲PublicationTelitaciceptApprovedPresentation
Phase 3 SLE results published in New England Journal of Medicine
systemic lupus erythematosussource ↗
▲Oral PresentationTelitaciceptApprovedPresentation
Positive Phase 3 results in IgAN presented at ASN Kidney Week 2025
IgA nephropathysource ↗
●Management ChangeCorporate
Appointment of Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer
◆Oral PresentationPresentation
Fireside chat at Stifel 2025 Virtual Immunology and Inflammation Forum
Past FDA Catalysts and PDUFA Decisions
How VOR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-11-08 | Telitacicept | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D29 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 73%
Micro Cap(rank 482 of 660)
Percentile Rank
Vor Biopharma Inc. faces pipeline headwinds (29/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Telitacicept Monoclonal antibodyNCT07404865 | Primary Sjogren's Disease | Phase 3 | RECRUITING | 250 | Jan 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every VOR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| telitacicept | generalized myasthenia gravis | Phase 3 | 2026-09-29 | 42%; 94%; ≥5-point MG-ADL improvement; 23.7%; 86.7%; 83-85%; 51%; 21%Read More | Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia GravisRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P.10% Owner | Option | 500 500 held | $12.80 | 10/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VOR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 2.5 % (-10.7 %) | 104.44 M | 5.67 M |
VOR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VOR ranks across every disease it competes in
Competitive Position is a premium feature
See how VOR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVOR News
VORVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio has granted stock options and restricted stock units to nine new employees as part of its inducement plan under Nasdaq Listing Rule 5635(c)(4). The stock options, totaling 59,250 shares, have a ten-year term with an exercise price of $18.06. The RSUs represent 12,550 shares and both will vest over four years, contingent on continued employment.
Read more →VORTelitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
Vor Bio announced positive results from a post hoc analysis of telitacicept in a Phase 3 trial for generalized myasthenia gravis. The study showed that 42% of participants achieved minimal symptom expression over 48 weeks, with a high rate of sustained responses. The findings were presented at the AANEM Annual Meeting, highlighting the potential of telitacicept to improve patient outcomes.
Read more →VORVor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
Vor Bio has completed enrollment in its global Phase 3 trial, UPSTREAM MG, for telitacicept in generalized myasthenia gravis. The company plans to expand its development program into ocular myasthenia gravis with the initiation of UPSTREAM oMG, also expected to start in 2027. Topline results for the primary endpoint are anticipated in the first half of 2027.
Read more →VORVor Bio To Participate in Upcoming September Conferences
Vor Bio announced its participation in several upcoming investor conferences in September 2026. The conferences include the Wells Fargo 21st Annual Healthcare Conference and the Citi Biopharma Back to School Conference, among others. These events will feature fireside chats and one-on-one meetings, providing opportunities for investor engagement.
Read more →VORVor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Vor Bio has reported its second quarter 2026 financial results, highlighting that enrollment is on track for the Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis. Additionally, enrollment is ongoing for the Phase 3 UPSTREAM trial in primary Sjögren’s disease. The company also noted a robust cash and investment balance of $514.5 million.
Read more →VORVor Bio Appoints David Zaccardelli to Board of Directors
Vor Bio has appointed David Zaccardelli to its Board of Directors, bringing over 20 years of biopharmaceutical leadership experience. His previous successes include leading Verona Pharma through significant growth and FDA approval. Zaccardelli's expertise is expected to aid Vor Bio in advancing telitacicept through global Phase 3 development for autoimmune diseases.
Read more →VORTelitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
Vor Bio's telitacicept has received approval from China's NMPA for treating Sjögren's disease, marking it as the first therapy approved for this condition in the country. The approval is based on positive Phase 3 trial results demonstrating significant improvements in disease activity and patient-reported outcomes. This is the fifth indication for telitacicept, which is also being developed for other autoimmune diseases.
Read more →VORTelitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
Vor Bio's telitacicept has received conditional approval from China's NMPA for the treatment of IgA nephropathy (IgAN), marking it as the first approved BAFF/APRIL-targeting therapy for this condition. The approval is based on positive efficacy results from the Phase 3 TELIGAN trial, which showed significant reductions in urinary protein-to-creatinine ratio. Vor Bio maintains exclusive rights for global commercialization, while RemeGen is responsible for its development within China. This approval underscores the potential of telitacicept in addressing the underlying immunological aspects of IgAN and other autoimmune diseases.
Read more →VOR▼ -6.2%on this news
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 1, 2026
Vor Bio has granted stock options and restricted stock units to 10 new employees as part of its inducement plan under Nasdaq Listing Rule 5635(c)(4). The stock options have a ten-year term with an exercise price equal to the closing price on the grant date. The vesting schedule for both stock options and RSUs spans four years, contingent on continued employment.
Read more →VORVor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
Vor Bio will participate in the 2026 Jefferies Global Healthcare Conference, providing a corporate update during a fireside chat. The presentation is scheduled for June 3, 2026, and will be accessible via a live webcast. Vor Bio is focused on advancing its telitacicept treatment for autoimmune diseases through Phase 3 clinical development.
Read more →VOR▼ -5.3%on this news
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
Vor Bio has announced positive interim analysis results from the Phase 3 TELIGAN trial of telitacicept, published in The New England Journal of Medicine. The study reported a significant 55% relative reduction in proteinuria and stable kidney function after 39 weeks of treatment compared to placebo. The results suggest the potential of telitacicept as a leading therapy for IgA nephropathy and other autoimmune diseases. The therapy is currently undergoing regulatory evaluations and might be positioned as a best-in-class dual BAFF/APRIL treatment.
Read more →VORVor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Vor Bio reported its financial results for Q1 2026, highlighting ongoing enrollment in Phase 3 trials for telitacicept in generalized myasthenia gravis and primary Sjögren’s disease. The company maintains a strong cash position of $491.5 million, expected to support operations until early 2029. Despite an increased net loss, the company is optimistic about the potential of telitacicept as a foundational therapy in autoimmune diseases.
Read more →VORVor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Vor Bio has reported its financial results for Q4 and full year 2025, highlighting the initiation of a global Phase 3 trial for telitacicept in primary Sjögren's disease. The company secured a $75 million private placement to support its clinical development efforts. Despite a significant net loss for the year, Vor Bio maintains a strong cash position, expected to fund operations into early 2029.
Read more →VORVor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease
Vor Bio has initiated the Phase 3 UPSTREAM SjD trial by dosing the first patient with telitacicept for primary Sjögren’s disease. This trial aims to evaluate the efficacy and safety of telitacicept, a unique BAFF/APRIL inhibitor, in a patient population that currently lacks approved disease-modifying therapies. The trial will involve approximately 250 patients and assess key disease activity metrics.
Read more →VOR▲ +6.7%on this news· ran to +28% by day 3shared move
Vor Bio Announces $75 Million Private Placement with TCGX
Vor Bio has announced a $75 million private placement to fund the clinical development of telitacicept, a treatment for autoimmune diseases. The financing, led by TCGX, will support ongoing Phase 3 trials for generalized myasthenia gravis and primary Sjögren's disease. The private placement is expected to close around March 30, 2026.
Read more →About Vor Biopharma Inc.
Headquarters500 BOYLSTON STREET, BOSTON, MA, 02116
BIOPHARMAWATCH ELITE PLUS
Trade the next VOR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime